MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

GlycoMimetics Company Profile (NASDAQ:GLYC)

Consensus Ratings for GlycoMimetics (NASDAQ:GLYC) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.50 (58.18% upside)

Analysts' Ratings History for GlycoMimetics (NASDAQ:GLYC)
Show:
DateFirmActionRatingPrice TargetActions
5/4/2016Canaccord GenuityReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Jefferies GroupLower Price TargetBuy$14.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2015Stifel NicolausBoost Price TargetBuy$13.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for GlycoMimetics (NASDAQ:GLYC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/4/2016Q116($0.47)($0.40)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q4($0.38)($0.47)$35.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015($0.40)$0.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.22)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2014Q314$0.21($0.35)$10.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014($0.08)$0.39$9.08 million$15.03 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.29)($0.30)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2014($2.17)($2.80)$9.65 million$0.08 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for GlycoMimetics (NASDAQ:GLYC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.46)($0.46)($0.46)
Q2 20161($0.46)($0.46)($0.46)
Q3 20161($0.54)($0.54)($0.54)
Q4 20161($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)
Dividend History for GlycoMimetics (NASDAQ:GLYC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for GlycoMimetics (NASDAQ:GLYC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/4/2016Mark Alan GoldbergDirectorBuy10,397$4.77$49,593.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Michael A HenosDirectorSell21,257$8.52$181,109.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Michael A HenosDirectorSell6,725$8.97$60,323.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Michael A HenosDirectorSell1,604$8.98$14,403.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014Michael A HenosDirectorBuy11,000$6.39$70,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Enterprise Associates 13 L NewMajor ShareholderBuy512,500$8.00$4,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014M James BarrettDirectorBuy1,000,000$8.00$8,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for GlycoMimetics (NASDAQ:GLYC)
DateHeadline
06/28/16 08:11 AMGlycoMimetics Doses First Patient in Phase 2 Portion of Clinical Trial of GMI-1271 in Newly Diagnosed Acute Myeloid Leukemia - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced dosing of the first patient with newly diagnosed acute myeloid leukemia (AML) in the Phase 2 portion of its ongoing ...
06/18/16 03:50 PMGlycoMimetics (GLYC) Prices 3.3M Common Stock Offering at $6.10/Share
06/17/16 03:13 PMGLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements -
06/17/16 01:18 PM5 Biggest Mid-Day Losers For Friday -   GlycoMimetics Inc (NASDAQ: GLYC) shares fell 18.69 percent to $5.99. GlycoMimetics priced public offering of 3.3 million shares at $6.10 per share. Innocoll Holdings PLC (NASDAQ: INNL) shares declined 14.90 percent to $6.26. Innocoll Holdings priced its 5.725 million share offering at $7.00 ...Full story available on Benzinga.com
06/17/16 09:19 AMGlycoMimetics Announces Pricing of Public Offering of Common Stock - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing ...
06/16/16 03:49 PMGlycoMimetics Announces Proposed Public Offering of Common Stock - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC), a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it ...
06/15/16 08:54 AMGlycoMimetics' GMI-1271 receives US FDA Fast Track status for acute myeloid leukemia treatment
06/14/16 09:01 AMGlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
06/13/16 08:19 AMGlycoMimetics' GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist ...
06/10/16 04:25 PMGlycoMimetics’ GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML
06/10/16 05:11 AMGLYCOMIMETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/10/16 05:09 AMGlycoMimetics' GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML - [at noodls] - Data presented via poster at European Hematology Association 21st Congress ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced data from the Phase 1 portion of its Phase ...
06/06/16 04:05 PMGlycoMimetics (GLYC) Commences Dosing of GMI-1271 Phase 2 in AML
06/06/16 08:00 AMGlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia - [Business Wire] - GlycoMimetics, Inc. today announced dosing of the first patient with relapsed/refractory acute myeloid leukemia in the Phase 2 portion of its ongoing Phase 1/2 clinical trial evaluating its novel E-selectin antagonist, GMI-1271, combined with induction chemotherapy.
06/02/16 04:27 PMGLYCOMIMETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/02/16 08:15 AMGlycoMimetics to Present at Jefferies 2016 Healthcare Conference - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Financial Officer Brian Hahn will provide a company overview at the Jefferies 2016 Healthcare Conference ...
05/26/16 08:39 AMWill GlycoMimetics (GLYC) Continue to Surge Higher? -
05/25/16 01:05 PMScientists block breast cancer cells from hiding in bones - The authors cite one disclosure: John Magnani is vice president and chief scientific officer of GlycoMimetics Inc. GlycoMimetics has a patent for GMI-1271, which was used in the study to inhibit E-selectin in breast cancer cells. Disclaimer: AAAS and ...
05/25/16 01:00 PMGlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine - [Business Wire] - GlycoMimetics, Inc. today announced that the peer-reviewed journal, Science Translational Medicine, has published preclinical research in its May 25 issue pointing to a potential clinical application for GMI-1271 in the treatment of breast cancer.
05/19/16 12:51 PMGLYCOMIMETICS INC : Submission of Matters to a Vote of Security Holders (form 8-K) - Item 5.07 Submission of Matters to a Vote of Security Holders. On May 17, 2016, GlycoMimetics, Inc. (the "Company") held its 2016 annual meeting of stockholders (the "Annual Meeting"). The stockholders considered two proposals, each of which is described ...
05/19/16 10:02 AMInitial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy ...
05/19/16 08:30 AMInitial Efficacy Data for GlycoMimetics’ GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress - [Business Wire] - GlycoMimetics, Inc. today announced that initial efficacy data from a Phase 1/2 clinical trial on the effects of drug candidate GMI-1271 combined with chemotherapy on patients with acute myeloid leukemia were accepted as a poster to be presented at the European Hematology Association’s 21st Congress, taking place June 9-12 in Copenhagen, Denmark.
05/18/16 02:37 PMGLYCOMIMETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/04/16 08:37 AMGLYCOMIMETICS INC Files SEC form 10-Q, Quarterly Report -
05/04/16 08:10 AMGlycoMimetics Reports First Quarter 2016 Results - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported financial results for the first quarter ended March 31, 2016. ... This is an abstract of the original noodl. To continue ...
05/04/16 08:06 AMGlycoMimetics reports 1Q loss -
04/26/16 08:06 AMGlycoMimetics Data On GMI-1271 Treatment Of Acetaminophen-Triggered Liver Toxicity To Be Presented At "Digestive Disease Week" Conference - GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at " Digestive Disease Week ...
04/25/16 03:30 PMGlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at “Digestive Disease Week” Conference - [Business Wire] - GlycoMimetics, Inc. today announced that collaborative research on the effects of its clinical drug candidate GMI-1271 on E-selectin, and acetaminophen- induced liver damage was accepted for an oral presentation at “Digestive Disease Week,” the annual meeting of the American Gastroenterological Association, American Association for the Study of Liver Diseases, American Society for Gastrointestinal ...
04/18/16 08:11 AMSecond Annual Regional BioTech Forum Brings Industry, Academia, Government Together to Raise Region’s Prominence as Top Biotech Hub - For more information, visit www.techcouncilmd.com. About GlycoMimetics, Inc. GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases ...
03/21/16 09:19 AMGLYCOMIMETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure -
03/21/16 08:41 AMGlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors - [at noodls] - GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and ...
03/17/16 08:30 AMGlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016 - [Business Wire] - GlycoMimetics, Inc. announced today that pre-clinical research demonstrating the potential of its third drug candidate, GMI-1359, will be presented at the American Association for Cancer Research Annual Meeting 2016 in New Orleans.
03/10/16 10:17 AMGlycoMimetics, Inc. :GLYC-US: Earnings Analysis: 2015 By the Numbers -
03/03/16 01:25 PMGlycoMimetics (GLYC) Reports Encouraging Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients - GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that of the first 13 evaluable patients in its clinical trial of GMI-1271 in combination with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML), investigators have observed ...
03/02/16 07:31 AM8:31 am GlycoMimetics announces initial clinical trial data from phase 1 portion of clinical trial for GMI-1271 in AML patients -
03/02/16 07:30 AMGlycoMimetics Announces Initial Clinical Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients - [Business Wire] - GlycoMimetics, Inc. today announced that of the first 13 evaluable patients in its clinical trial of GMI-1271 in combination with chemotherapy in patients with relapsed/refractory acute myeloid leukemia , investigators have observed clinical responses in eight patients, for an overall response rate of 62%.
03/01/16 03:36 PMGLYCOMIMETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
03/01/16 01:17 PMGLYCOMIMETICS : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - 02/11 GLYCOMIMETICS: to Present at 18th Annual BIO CEO & Investor Conference 02/01 GLYCOMIMETICS: to Present at 18th Annual BIO CEO & Investor Conference 2015 GLYCOMIMETICS: Highlights Preclinical Data in Oral Presentation at ASH Meeting .. 2015 ...
03/01/16 08:30 AMGlycoMimetics to Present at Cowen and Company’s 36th Annual Health Care Conference - [Business Wire] - GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at Cowen and Company’s 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 8:00 a.m.
02/29/16 05:17 PMGlycoMimetics reports 4Q loss -
02/29/16 04:00 PMGlycoMimetics Reports Fourth Quarter and Year-End 2015 Results - [Business Wire] - GlycoMimetics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2015. As of December 31, 2015, GlycoMimetics had cash and cash equivalents of $46.8 million, which reflects a $20.0 million non-refundable milestone payment received from Pfizer Inc.
02/15/16 10:49 AMRecent Study: Prostate Cancer - Pipeline Review, H2 2015 - Inc., Glactone Pharma AB, GlaxoSmithKline Plc, GlycoMimetics, Inc., GP Pharm, S.A., GTx, Inc., Hadasit Medical Research Services & Development Ltd, Humanetics Corporation, Huperion Sarl, Hybrigenics S.A., IC-MedTech, Inc., IGF Oncology, LLC., Ignyta ...
02/05/16 10:32 AMSEC Announces Advisory Committee on Small and Emerging Companies Members - GlycoMimetics Inc., Rockville, Maryland Kyle Hauptman, Executive Director of the Main Street Growth Project, Washington, D.C. Jenny Kassan, owner, Jenny Kassan Consulting, Fremont, California Catherine V. Mott, founder and CEO, BlueTree Capital Group ...
02/01/16 03:33 PMGlycoMimetics to Present at 18th Annual BIO CEO & Investor Conference - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- (: GLYC) today announced that Chief Executive Officer will provide a company overview at the 18 Annual BIO CEO & Investor Conference on at at the Waldorf Astoria in . ...
12/07/15 09:42 AMGlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model - [at noodls] - IND filing for GMI-1359 planned for mid-2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that preclinical data presented in a poster at the 57thAmerican Society ...
12/05/15 10:53 AMGlycoMimetics Presents at ASH Meeting First-in-Human Data Showing Favorable Safety, Metabolic and Biomarker Profiles for GMI-1271 - [at noodls] - Initial top-line readout from on-going AML trial with GMI-1271 anticipated for mid 2016 ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) presented in a poster at the 57th American Society ...
12/05/15 09:00 AMGlycoMimetics Poster Shows GMI-1271 Reverses Drug Resistance in Multiple Myeloma Models - [Business Wire] - GlycoMimetics, Inc. announced today that preclinical data presented in a poster at the 57th American Society of Hematology Annual Meeting and Exposition, in Orlando, Florida, on its drug candidate GMI-1271 showed the compound could reverse molecular mechanisms of chemotherapy resistance seen in multiple myeloma.
12/01/15 08:10 AMMarket Update on Movers and Shakers - Research on LMI Aerospace, TriVascular Technologies, Stratus Properties and GlycoMimetics - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 1, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: LMI Aerospace ...
11/12/15 03:26 PMGlycoMimetics to Present at Two Investor Conferences in November - [at noodls] - ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Chief Executive Officer Rachel King will present in November at two investor conferences, as follows: The Stifel ...
11/12/15 09:11 AMGlycoMimetics reports 3Q loss -
About GlycoMimetics

GlycoMimetics logoGlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLYC
  • CUSIP:
Key Metrics:
  • Previous Close: $7.16
  • 50 Day Moving Average: $7.43
  • 200 Day Moving Average: $6.05
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $140.67M
  • Current Quarter EPS Consensus Estimate: $-1.82 EPS
Additional Links:
GlycoMimetics (NASDAQ:GLYC) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha